Improvement by eicosanoids in cancer cachexia induced by LLC-IL6 transplantation

T. Ohira, K. Nishio, Y. Ohe, H. Arioka, M. Nishio, Y. Funayama, H. Ogasawara, M. Fukuda, Kazunaga Yazawa, H. Kato, N. Saijo

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Cachexia frequently occurs in the late stages of cancer, and is difficult to manage. We previously reported that interleukin-6 (IL-6) cDNA transfection into Lewis lung carcinoma (LLC-IL6) induced cachexia-like symptoms in C57BL/6 mice. This was thought to be a useful experimental model of cancer cachexia. We have examined the effects of two eicosanoids, docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), in order to evaluate whether they could relieve cachexia. LLC-IL6-bearing animals were divided into three treatment groups receiving DHA, EPA or water as the control; 80-μl samples of these compounds (purity > 95%) were administered orally by catheter daily starting 7 days after tumor transplantation. Tumor growth curves were similar in the three groups. There were no differences in water or food intake in the three groups. However, body weight, a marker of cachexia, was significantly higher in treated mice than in the control group. Sixteen days after tumor transplantation, the mean body weight was 17.45 g (P < 0.05), 17.2 g and 16.41 g in the groups receiving DHA, EPA and water respectively. The eicosanoids did not affect serum levels of IL-6. Ubiquitination of muscle protein, a marker of proteolysis coupled to cachexia, was compared in LLC-IL6- and LLC-transplanted mice. The eicosanoids prevented the ubiquitination of approximately 180 kDa protein. These results suggest that eicosanoids may prevent the cachexia mediated by IL-6.

Original languageEnglish
Pages (from-to)711-715
Number of pages5
JournalJournal of Cancer Research and Clinical Oncology
Volume122
Issue number12
Publication statusPublished - 1996
Externally publishedYes

Fingerprint

Cachexia
Eicosanoids
Interleukin-6
Transplantation
Eicosapentaenoic Acid
Docosahexaenoic Acids
Neoplasms
Ubiquitination
Body Weight
Lewis Lung Carcinoma
Water
Muscle Proteins
Inbred C57BL Mouse
Proteolysis
Drinking
Transfection
Theoretical Models
Catheters
Complementary DNA
Eating

Keywords

  • cancer cachexia
  • docosahexaenoic acid
  • eicosanoid
  • eicosapentaenoic acid
  • IL-6

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Ohira, T., Nishio, K., Ohe, Y., Arioka, H., Nishio, M., Funayama, Y., ... Saijo, N. (1996). Improvement by eicosanoids in cancer cachexia induced by LLC-IL6 transplantation. Journal of Cancer Research and Clinical Oncology, 122(12), 711-715.

Improvement by eicosanoids in cancer cachexia induced by LLC-IL6 transplantation. / Ohira, T.; Nishio, K.; Ohe, Y.; Arioka, H.; Nishio, M.; Funayama, Y.; Ogasawara, H.; Fukuda, M.; Yazawa, Kazunaga; Kato, H.; Saijo, N.

In: Journal of Cancer Research and Clinical Oncology, Vol. 122, No. 12, 1996, p. 711-715.

Research output: Contribution to journalArticle

Ohira, T, Nishio, K, Ohe, Y, Arioka, H, Nishio, M, Funayama, Y, Ogasawara, H, Fukuda, M, Yazawa, K, Kato, H & Saijo, N 1996, 'Improvement by eicosanoids in cancer cachexia induced by LLC-IL6 transplantation', Journal of Cancer Research and Clinical Oncology, vol. 122, no. 12, pp. 711-715.
Ohira T, Nishio K, Ohe Y, Arioka H, Nishio M, Funayama Y et al. Improvement by eicosanoids in cancer cachexia induced by LLC-IL6 transplantation. Journal of Cancer Research and Clinical Oncology. 1996;122(12):711-715.
Ohira, T. ; Nishio, K. ; Ohe, Y. ; Arioka, H. ; Nishio, M. ; Funayama, Y. ; Ogasawara, H. ; Fukuda, M. ; Yazawa, Kazunaga ; Kato, H. ; Saijo, N. / Improvement by eicosanoids in cancer cachexia induced by LLC-IL6 transplantation. In: Journal of Cancer Research and Clinical Oncology. 1996 ; Vol. 122, No. 12. pp. 711-715.
@article{32f9c41b834845a0a18bd9a8debb5150,
title = "Improvement by eicosanoids in cancer cachexia induced by LLC-IL6 transplantation",
abstract = "Cachexia frequently occurs in the late stages of cancer, and is difficult to manage. We previously reported that interleukin-6 (IL-6) cDNA transfection into Lewis lung carcinoma (LLC-IL6) induced cachexia-like symptoms in C57BL/6 mice. This was thought to be a useful experimental model of cancer cachexia. We have examined the effects of two eicosanoids, docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), in order to evaluate whether they could relieve cachexia. LLC-IL6-bearing animals were divided into three treatment groups receiving DHA, EPA or water as the control; 80-μl samples of these compounds (purity > 95{\%}) were administered orally by catheter daily starting 7 days after tumor transplantation. Tumor growth curves were similar in the three groups. There were no differences in water or food intake in the three groups. However, body weight, a marker of cachexia, was significantly higher in treated mice than in the control group. Sixteen days after tumor transplantation, the mean body weight was 17.45 g (P < 0.05), 17.2 g and 16.41 g in the groups receiving DHA, EPA and water respectively. The eicosanoids did not affect serum levels of IL-6. Ubiquitination of muscle protein, a marker of proteolysis coupled to cachexia, was compared in LLC-IL6- and LLC-transplanted mice. The eicosanoids prevented the ubiquitination of approximately 180 kDa protein. These results suggest that eicosanoids may prevent the cachexia mediated by IL-6.",
keywords = "cancer cachexia, docosahexaenoic acid, eicosanoid, eicosapentaenoic acid, IL-6",
author = "T. Ohira and K. Nishio and Y. Ohe and H. Arioka and M. Nishio and Y. Funayama and H. Ogasawara and M. Fukuda and Kazunaga Yazawa and H. Kato and N. Saijo",
year = "1996",
language = "English",
volume = "122",
pages = "711--715",
journal = "Journal of Cancer Research and Clinical Oncology",
issn = "0171-5216",
publisher = "Springer Verlag",
number = "12",

}

TY - JOUR

T1 - Improvement by eicosanoids in cancer cachexia induced by LLC-IL6 transplantation

AU - Ohira, T.

AU - Nishio, K.

AU - Ohe, Y.

AU - Arioka, H.

AU - Nishio, M.

AU - Funayama, Y.

AU - Ogasawara, H.

AU - Fukuda, M.

AU - Yazawa, Kazunaga

AU - Kato, H.

AU - Saijo, N.

PY - 1996

Y1 - 1996

N2 - Cachexia frequently occurs in the late stages of cancer, and is difficult to manage. We previously reported that interleukin-6 (IL-6) cDNA transfection into Lewis lung carcinoma (LLC-IL6) induced cachexia-like symptoms in C57BL/6 mice. This was thought to be a useful experimental model of cancer cachexia. We have examined the effects of two eicosanoids, docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), in order to evaluate whether they could relieve cachexia. LLC-IL6-bearing animals were divided into three treatment groups receiving DHA, EPA or water as the control; 80-μl samples of these compounds (purity > 95%) were administered orally by catheter daily starting 7 days after tumor transplantation. Tumor growth curves were similar in the three groups. There were no differences in water or food intake in the three groups. However, body weight, a marker of cachexia, was significantly higher in treated mice than in the control group. Sixteen days after tumor transplantation, the mean body weight was 17.45 g (P < 0.05), 17.2 g and 16.41 g in the groups receiving DHA, EPA and water respectively. The eicosanoids did not affect serum levels of IL-6. Ubiquitination of muscle protein, a marker of proteolysis coupled to cachexia, was compared in LLC-IL6- and LLC-transplanted mice. The eicosanoids prevented the ubiquitination of approximately 180 kDa protein. These results suggest that eicosanoids may prevent the cachexia mediated by IL-6.

AB - Cachexia frequently occurs in the late stages of cancer, and is difficult to manage. We previously reported that interleukin-6 (IL-6) cDNA transfection into Lewis lung carcinoma (LLC-IL6) induced cachexia-like symptoms in C57BL/6 mice. This was thought to be a useful experimental model of cancer cachexia. We have examined the effects of two eicosanoids, docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), in order to evaluate whether they could relieve cachexia. LLC-IL6-bearing animals were divided into three treatment groups receiving DHA, EPA or water as the control; 80-μl samples of these compounds (purity > 95%) were administered orally by catheter daily starting 7 days after tumor transplantation. Tumor growth curves were similar in the three groups. There were no differences in water or food intake in the three groups. However, body weight, a marker of cachexia, was significantly higher in treated mice than in the control group. Sixteen days after tumor transplantation, the mean body weight was 17.45 g (P < 0.05), 17.2 g and 16.41 g in the groups receiving DHA, EPA and water respectively. The eicosanoids did not affect serum levels of IL-6. Ubiquitination of muscle protein, a marker of proteolysis coupled to cachexia, was compared in LLC-IL6- and LLC-transplanted mice. The eicosanoids prevented the ubiquitination of approximately 180 kDa protein. These results suggest that eicosanoids may prevent the cachexia mediated by IL-6.

KW - cancer cachexia

KW - docosahexaenoic acid

KW - eicosanoid

KW - eicosapentaenoic acid

KW - IL-6

UR - http://www.scopus.com/inward/record.url?scp=10544228529&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10544228529&partnerID=8YFLogxK

M3 - Article

C2 - 8954167

AN - SCOPUS:10544228529

VL - 122

SP - 711

EP - 715

JO - Journal of Cancer Research and Clinical Oncology

JF - Journal of Cancer Research and Clinical Oncology

SN - 0171-5216

IS - 12

ER -